OTC Markets
Prev Close 0.10
Day Low/High 0.09 / 0.10
52 Wk Low/High 0.09 / 2.75
Exchange OTC Markets
Shares Outstanding 21.18B
Market Cap 2.12M
Div & Yield N.A. (N.A)

Propanc Biopharma Completes Successful Reproduction Run For PRP

Company Requests Scientific Advice Meeting with the MHRA (UK) to Discuss Next Steps

Propanc Biopharma Receives Allowance Of Key Patent Application In The EU

Patent covers a pharmaceutical composition for treating cancer comprising trypsinogen and chymotrypsinogen within the European Union

Propanc Biopharma Repays Magna Invests Senior Secured Convertible Debentures

CEO Views as "Positive First Step" towards Restructuring Balance Sheet to Attract Long Term Investors

Propanc Biopharma Is Readied for Revolutionary Cancer Treatment, CEO Says

With a promising treatment for solid tumor cancers coming down its pipeline, Propanc has its sights set on changing the way cancer is treated.

Propanc Biopharma Advances Towards GMP Manufacture Of PRP For Human Trials

Purification Process Achieves Pure and Stable Active Drug Substances, Engineering Runs to Commence